Stop Smoking | Shim Clinic, Singapore
Stop Smoking Clinic Singapore: Quit/stop smoking with the medication varenicline (Champix®/Chantix®). Smoking cessation clinic, Singapore. Private and confidential service. Definitions, references, and latest news.
Keywords: Stop Smoking Clinic Singapore, Singapore Stop Smoking Clinic, Stop Smoking Singapore, Singapore Stop Smoking, Stop Smoking.
Quit smoking with the medication varenicline (Champix® / Chantix®). Revolutionary new way to stop smoking at our smoking cessation clinic. Get away from the harmful effects of smoking, without feeling the effects of withdrawal!
Smoking cessation program cost:
|Champix® starter pack||SG$108 |
|Champix® 2 week continuation pack x5||SG$605 |
|Total cost:||SG$751 |
Reassessing the safety of varenicline.
Sun, 01 Dec 2013 05:00:00 +0100 | The American Journal of Psychiatry
Authors: Evins AE
Quit-smoking drug to make problem drinking 'social'
Thu, 28 Nov 2013 10:00:00 +0100 | Health News from Medical News Today
A drug commonly used to help people quit smoking may also help problem drinkers overcome their addiction.Professor Selena Bartlett from QUT's Institute of Health and Biomedical Innovation (IHBI) and an ambassador for Women in Technology (WiT) said trials would soon begin to test whether varenicline, commonly known as Champix, can effectively treat problem drinkers."It's well known that many people with serious alcohol dependency also smoke so we've been trying to better understand the mechanisms behind that," Professor Bartlett said. (Source: Health News from Medical News Today)
Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use
Thu, 21 Nov 2013 05:00:00 +0100 | Evidence-Based Medicine
Commentary on: Cahill K, Stevens S, Perera R, et al..Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev2013;(5):CD009329. Context If current trends continue, tobacco use will cause one billion premature deaths globally this century.1 Predominantly in the form of cigarettes, smoking causes 12% of male and 6% female deaths around the world annually.2 Preventing tobacco-related diseases in cigarette smokers commonly requires treatment; and pharmacotherapy is a cornerstone of therapy. Several pharmacotherapies are currently available and others have been evaluated and abandoned. Understanding their comparative efficacies and risks will help guide treatment, policy and future research. Methods Cahill and colleagues searched the...
Phase II Crossover Trial of Varenicline in Mild-to-Moderate Alzheimer's Disease.
Wed, 20 Nov 2013 17:56:11 +0100 | Dementia and Geriatric Cognitive Disorders
Conclusions: Varenicline did not improve cognition, behavior or global change in this population. The most frequent varenicline-associated AEs were gastrointestinal; psychiatric AEs were rare and similar between the groups. © 2013 S. Karger AG, Basel.
The effect of varenicline on the development and expression of nicotine‐induced behavioral sensitization and cross‐sensitization in rats
Wed, 20 Nov 2013 05:00:00 +0100 | Addiction Biology
Varenicline induced acute interstitial nephritis in the setting of idiopathic membranous glomerulonephritis
Mon, 11 Nov 2013 05:00:00 +0100 | BMC Nephrology
Managing tobacco use: the neglected cardiovascular disease risk factor
Thu, 07 Nov 2013 05:00:00 +0100 | European Heart Journal
Cigarette smoking is a major risk factor for cardiovascular disease (CVD) and the leading avoidable cause of death worldwide. Exposure to secondhand smoke (SHS) increases the risk of CVD among non-smokers. Smoking cessation benefits all smokers, regardless of age or amount smoked. The excess risk of CVD is rapidly reversible, and stopping smoking after a myocardial infarction reduces an individual's risk of CVD mortality by 36% over 2 years. Smoking cessation is a key component of primary and secondary CVD prevention strategies, but tobacco use often receives less attention from cardiologists than other risk factors, despite the availability of proven treatments that improve smoking cessation rates. Both psychosocial counselling and pharmacotherapy are effective methods to help smokers qui...
Tennessee Health Plan Tobacco Cessation Coverage
Fri, 01 Nov 2013 04:00:00 +0100 | Public Health Nursing
ConclusionIn 2012, Tennessee fell short of Healthy People goals for total managed care and comprehensive TennCare coverage of smoking cessation. If Tennessee mandates that all health plans provide full coverage, 481,900 smokers may immediately be in a better position to quit. (Source: Public Health Nursing)
Relative Potency of Varenicline or Fluvoxamine to Reduce Responding for Ethanol Versus Food Depends on the Presence or Absence of Concurrently Earned Food
Tue, 29 Oct 2013 04:00:00 +0100 | Alcoholism: Clinical and Experimental Research
ConclusionsThese results demonstrate that selective effects on drug‐ versus alternative‐maintained behavior depend on the schedule arrangement, and assays in which EtOH or an alternative is the only programmed reinforcement may overestimate the selectivity of treatments to decrease EtOH self‐administration. Thus selective effects obtained under one assay may not generalize to another. Better understanding the behavioral mechanisms responsible for these results may help to guide pharmacotherapeutic development for substance use disorders. (Source: Alcoholism: Clinical and Experimental Research)
Commitment Contracts and Team Incentives: A Randomized Controlled Trial for Smoking Cessation in Thailand
Sat, 19 Oct 2013 04:15:49 +0100 | American Journal of Preventive Medicine
Conclusions: The intervention enhanced abstinence by 91%–136% at 6 months, relative to the control group, although self-reports at 14 months suggest tapering of the treatment effect. The intervention may offer a viable, cost-effective alternative to current smoking-cessation approaches in low-resource settings.Trial registration: This study is registered at ClinicalTrials.gov NCT01311115. (Source: American Journal of Preventive Medicine)